导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.17% | 1298/2676 |
| 近一周 | -1.53% | 1240/3004 |
| 近一月 | -3.57% | 1394/2984 |
| 近一季 | -10.10% | 1975/2896 |
| 近半年 | -2.52% | 1218/2746 |
| 近一年 | 4.63% | 999/2519 |
| 近两年 | 62.46% | 678/1796 |
| 近三年 | 40.03% | 429/1340 |
| 成立以来 | 67.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.37% 2766/4961 |
16.88% 1520/5312 |
- - |
- - |
| 2025 | 28.70% 1462/4813 |
0.21% 1946/3635 |
2.39% 1599/4076 |
22.98% 1591/4524 |
2.00% 1117/4813 |
| 2024 | 15.96% 859/3463 |
2.13% 812/2808 |
-1.50% 1070/3014 |
12.04% 2426/3129 |
2.89% 879/3463 |
| 2023 | -12.70% 1499/2656 |
1.09% 1644/2280 |
-4.27% 1121/2385 |
-4.35% 1121/2515 |
-5.68% 1459/2655 |
| 2022 | -17.49% 598/2207 |
-14.25% 924/1919 |
6.87% 588/2016 |
-11.72% 569/2113 |
1.99% 1068/2208 |
| 2021 | 5.16% 555/1822 |
-2.81% 707/1255 |
9.47% 551/1330 |
-4.28% 697/1466 |
3.27% 454/1822 |
| 2020 | 41.49% 289/1250 |
-7.58% 554/1028 |
17.34% 377/1067 |
13.73% 311/1164 |
14.72% 255/1184 |
| 2019 | 38.89% 296/1092 |
26.99% 366/754 |
0.15% 193/804 |
0.48% 513/850 |
8.68% 299/918 |
| 2018 | -26.82% 403/834 |
- - |
- - |
- - |
-11.36% 285/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 平安沪深300指数量化A VS. 长安沪深300非周期A(740101) |